Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14151677 | 0.82 | GABRR1 (0.34) | PAX8LMNA | |
| SCHEMBL10946371 | 0.80 | — | — | |
| SCHEMBL8904629 | 0.80 | — | — | |
| SCHEMBL450548 | 0.76 | MPI (0.43) | AKR1B1LMNAALDH1A1 | |
| SCHEMBL4167823 | 0.76 | MPI (0.43) | AKR1B1LMNAALDH1A1 | |
| SCHEMBL17984942 | 0.76 | MPI (0.43) | AKR1B1LMNAALDH1A1 | |
| SCHEMBL1660690 | 0.76 | MPI (0.43) | AKR1B1LMNAALDH1A1 | |
| Glycerin SCHEMBL15556006 | 0.74 | LMNA (0.46) | AKR1B1PAX8LMNAALDH1A1USP2 | |
| SCHEMBL15855477 | 0.73 | AKR1B1 (0.39) | AKR1B1LMNAALDH1A1 | |
| SCHEMBL5035754 | 0.72 | AKR1B1 (0.34) | AKR1B1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2156181-B1 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | ADLYFE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8673579-B2 | Peptide probes for diagnostics and therapeutics | ADLYFE, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130108549-A1 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | ADLYFE, INC. | 2013-05-02 | — | — | US | disclosed |
| EP-2156181-A2 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | Adlyfe, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090274621-A1 | USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER | ADLYFE, INC | 2009-11-05 | — | — | US | disclosed |
| WO-2009117042-A1 | USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER | ADLYFE, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080095706-A1 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | ADLYFE, INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008013859-A2 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | ADLYFE, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274621-A1 | USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER | FABP7, NPPA, CNDP2 | AKR1B1 3097/4885PAX8 3255/4885LMNA 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.